Antibiotics impair immunotherapy for urothelial cancer

Nature Reviews Urology, Published online: 08 September 2020; doi:10.1038/s41585-020-0373-1Pooled clinical trial data reveal that antibiotics worsen progression-free survival and overall survival in patients with locally advanced and metastatic urothelial cancer receiving anti-PDL1 therapy. Consensus guidelines for antibiotic use in these patients, as well as diagnostic tools and corrective measures, are needed to decrease primary resistance to immune checkpoint inhibitors.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research